Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

Exclusion Criteria

• •HER2 positive tumours (defined as IHQ 3+ or positive fluorescence in situ hybridization \[FISH\]).
• •Prior systemic therapy for breast cancer (immunotherapy, hormonotherapy, chemotherapy).
• •Prior treatment with anthracyclines or taxanes (paclitaxel, docetaxel) for any previous malignancy.
• •Prior radiotherapy for breast cancer.
• •Bilateral invasive breast cancer.
• •Pregnant or lactating women.
• •Previous grade \>= 2 motor or sensorial neurotoxicity (National Cancer Institute Common Toxicity Criteria \[NCICTC\]).
• •Other serious comorbidities: congestive heart failure or unstable angina; prior history of myocardial infarction in previous year; uncontrolled hypertension (HT); high risk arrhythmias; history of significant neurological or psychiatric disorders; uncontrolled active infection; active peptic ulcer; unstable diabetes mellitus; dyspnea at rest; or chronic therapy with oxygen.
• •Previous or current history of neoplasms different from breast cancer, except for skin carcinoma, cervical in situ carcinoma, or any other tumor curatively treated and without recurrence in the last 10 years; ductal in situ carcinoma in the same breast; lobular in situ carcinoma.
• •Chronic treatment with corticosteroids.
• •Contraindications for administration of corticosteroids.
• •Concomitant treatment with other therapy for cancer.
• •Males.